Pittsburgh, Pennsylvania, October 5, 2026
Allegheny Health Network’s (AHN) Allegheny General Hospital (AGH) has launched participation in a clinical trial evaluating a new investigational therapy for pulmonary arterial hypertension (PAH), a serious and progressive cardiovascular condition that can lead to right-sided heart failure and death. The Pittsburgh-based hospital is currently the only participating study site in the tri-state region for the trial, giving eligible patients access to an investigational treatment being developed by Novartis. The double-blind, placebo-controlled study is designed to evaluate the safety, tolerability, and effectiveness of LTP001, an investigational medicine intended to target a protein believed to contribute to the abnormal changes associated with PAH.
Clinical Trial Targets Underlying PAH Disease Mechanism
The LTP001 clinical trial represents an effort to investigate a potential treatment approach that goes beyond conventional management of pulmonary arterial hypertension. PAH occurs when arteries in the lungs become narrowed or thickened, increasing resistance to blood flow and forcing the right side of the heart to work harder to circulate blood through the pulmonary system. Over time, this additional strain can cause enlargement of the right side of the heart and, in severe cases, heart failure. Existing pharmacological treatments can help relax pulmonary blood vessels and improve blood flow, but the investigational approach being evaluated in the trial is intended to target a biological pathway associated with the underlying vascular changes. According to AHN investigators, LTP001 is designed to block a protein involved in abnormal thickening of pulmonary arteries, potentially offering a strategy that could address disease progression in addition to reducing pulmonary blood pressure.
AHN Provides Access to Investigational PAH Therapy
The study is being led locally by Hayah Kassis-George, MD, a board-certified cardiologist specializing in pulmonary hypertension at AHN. The trial will assess the investigational medicine under a controlled study design to determine its potential benefits and risks in patients with PAH. AHN physicians emphasize that participation in clinical research can provide qualifying patients with access to emerging therapies while also generating evidence that could influence the future treatment landscape. PAH can be challenging to diagnose because symptoms may initially appear in otherwise healthy adults. Common symptoms include shortness of breath, fatigue, chest discomfort, and swelling in the legs, ankles, or abdomen. The condition is more frequently diagnosed in women between 30 and 60 years of age, and an estimated 500 to 1,000 people are newly diagnosed with PAH each year in the United States.
Advertisement
Specialized Pulmonary Hypertension Program Supports Research
AHN AGH combines its clinical trial capabilities with a specialized Pulmonary Hypertension Care Center, providing patients with advanced diagnostics, medical therapies, surgical options, and multidisciplinary support. The institution is one of only four designated Pulmonary Hypertension Care Centers in Pennsylvania and has extensive experience treating complex pulmonary vascular diseases. Its capabilities also include pulmonary thrombectomy, a highly complex surgical procedure used for certain patients with chronic thromboembolic pulmonary hypertension (CTEPH). In June 2025, AHN announced completion of its 100th CTEPH procedure. The hospital’s involvement in the LTP001 study further expands its role in advancing research for difficult-to-treat pulmonary vascular conditions. Through participation in the Novartis-sponsored clinical trial, AHN aims to contribute clinical evidence on a potential new treatment strategy for PAH while providing eligible patients in the region an opportunity to participate in innovative cardiovascular research. The study reflects continued efforts across the biopharmaceutical industry to develop therapies that may address the underlying biology of pulmonary arterial hypertension, rather than focusing solely on symptom management.
Source: Allegheny Health Network press release
